Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

Clarity Pharmaceuticals Ltd / Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/car-group-ltd" target="_blank" data-smartkarma-citation="entities:701:1" rel="noopener">CAR Group (CAR AU)</a> replaces <a href="https://www.smartkarma.com/entities/dexus" target="_blank" data-smartkarma-citation="entities:403:1" rel="noopener">Dexus Property (DXS AU)</a> in the S&amp;P/ASX50 Index and <a href="https://www.smartkarma.com/entities/clarity-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:34095:1" rel="noopener">Clarity Pharmaceuticals Ltd (CU6 AU)</a> replaces <a href="https://www.smartkarma.com/entities/spark-new-zealand-ltd-3dcc706a-f086-4dd4-882b-2a42a36ccf8d" target="_blank" data-smartkarma-citation="entities:26915:1" rel="noopener">Spark New Zealand (SPK AU)</a> in the <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX200 (AS51 INDEX)</a>.</li>
<li>
<a href="https://www.smartkarma.com/entities/dexus" target="_blank" data-smartkarma-citation="entities:403:1" rel="noopener">Dexus Property</a> and <a href="https://www.smartkarma.com/entities/spark-new-zealand-ltd" target="_blank" data-smartkarma-citation="entities:930:1" rel="noopener">Spark New Zealand</a> were deleted from a global index a couple of weeks ago, so this will heap further pressure and increase the real float of the stocks.</li>
<li>There has been an increase in cumulative excess volume for all changes, but positioning in some stocks may continue post the announcement.</li>
</ul>



CAR Group (CAR AU) replaces Dexus Property (DXS AU) in the S&amp;P/ASX50 Index and Clarity Pharmaceuticals Ltd (CU6 AU) replaces Spark New Zealand (SPK AU) in the S&amp;P/ASX200 (AS51 INDEX).

Dexus Property and Spark New Zealand were deleted from a global index a couple of weeks ago, so this will heap further pressure and increase the real float of the stocks.
There has been an increase in cumulative excess volume for all changes, but positioning in some stocks may continue post the announcement.


S&P/​​​​ASX Index Rebalance (Dec 2024): CAR, Clarity Pharma Added; Dexus, Spark Deleted

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/clarity-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:34095:1" rel="noopener">Clarity Pharmaceuticals Ltd (CU6 AU)</a> announced that two participants have been dosed with 64Cu-SAR-bisPSMA and imaged days after the commencement of the Co-PSMA Investigator-Initiated Trial (IIT).</li>
<li>SARTATE completes final assessment in Phase II diagnostic trial for neuroendocrine tumours. SAR-Bombesin began trial for castrate resistant prostate cancer.</li>
<li>Clarity’s copper platform, strong prostate pipeline, and therapeutic and diagnostic efficacy data represent an attractive opportunity to grow a significant radiopharmaceutical franchise in oncology and other indications.</li>
</ul>



Clarity Pharmaceuticals Ltd (CU6 AU) announced that two participants have been dosed with 64Cu-SAR-bisPSMA and imaged days after the commencement of the Co-PSMA Investigator-Initiated Trial (IIT).
SARTATE completes final assessment in Phase II diagnostic trial for neuroendocrine tumours. SAR-Bombesin began trial for castrate resistant prostate cancer.
Clarity’s copper platform, strong prostate pipeline, and therapeutic and diagnostic efficacy data represent an attractive opportunity to grow a significant radiopharmaceutical franchise in oncology and other indications.


Clarity Pharmaceuticals (CU6 AU): Well-Funded, Pipeline Progressing Well, Growth Prospects Galore

<ul>
<li>
<a href="https://www.smartkarma.com/entities/clarity-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:34095:1" rel="noopener">Clarity Pharmaceuticals Ltd (CU6 AU)</a> received FDA fast track designation for its lead candidate 64Cu-SAR-bisPSMA for PET imaging of prostate cancer lesions. Currently, 64Cu-SAR-bisPSMA is in phase 3 trial.</li>
<li>If approved, 64Cu-SAR-bisPSMA has the potential the best-in-class diagnostic as the product has improved lesion detection capability compared to existing prostate cancer diagnostics.</li>
<li>Clarity’s copper platform, strong prostate pipeline and therapeutic and diagnostic efficacy data represents an attractive opportunity to grow a significant radiopharmaceutical franchise in oncology and other indications.</li>
</ul>



Clarity Pharmaceuticals Ltd (CU6 AU) received FDA fast track designation for its lead candidate 64Cu-SAR-bisPSMA for PET imaging of prostate cancer lesions. Currently, 64Cu-SAR-bisPSMA is in phase 3 trial.
If approved, 64Cu-SAR-bisPSMA has the potential the best-in-class diagnostic as the product has improved lesion detection capability compared to existing prostate cancer diagnostics.
Clarity’s copper platform, strong prostate pipeline and therapeutic and diagnostic efficacy data represents an attractive opportunity to grow a significant radiopharmaceutical franchise in oncology and other indications.


Clarity Pharmaceuticals Ltd (CU6 AU): An Attractive Bet on Red Hot Radiopharmaceutical Field

External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

External broker reports(aggregated public sources)

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals with a revised risked PT of $4.50/share.</li><li>Evaluation of Clarity’s opportunity with their 64Cu-SARbisPSMA PET/CT agent in prostate cancer drives our upgrade in part – recognising that they have a unique agent with the potential to finally offer true clinical differentiation to existing approved agents, notably in biochemical recurrence (BCR).</li><li>We provide thoughts on steps forward here. The balance of our valuation uplift is being driven by re-evaluation of the two prostate cancer therapeutic (Tx) programs (67Cu-SARbisPSMA, 67Cu-SAR-BBN) and the sheer importance they hold to any potential acquirer of CU6. M&amp;A activity within Radiopharmaceuticals has been rampant and the hunt for companies with intellectual property coupled with impressive Tx pipelines has been at the forefront of (most) deals. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals with a revised risked PT of $4.50/share.Evaluation of Clarity’s opportunity with their 64Cu-SARbisPSMA PET/CT agent in prostate cancer drives our upgrade in part – recognising that they have a unique agent with the potential to finally offer true clinical differentiation to existing approved agents, notably in biochemical recurrence (BCR).We provide thoughts on steps forward here. The balance of our valuation uplift is being driven by re-evaluation of the two prostate cancer therapeutic (Tx) programs (67Cu-SARbisPSMA, 67Cu-SAR-BBN) and the sheer importance they hold to any potential acquirer of CU6. M&amp;A activity within Radiopharmaceuticals has been rampant and the hunt for companies with intellectual property coupled with impressive Tx pipelines has been at the forefront of (most) deals. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - O/W: Better Late than Fuzzy

<ul><li>We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.12/sh (unrisked $7.71/sh).</li><li>Clarity have recently completed a $110M institutional equity placement and entitlement offer (with ongoing retail component) that will see them funded through to CY26 including major trial programs for their PSMA directed assets (64Cu/67Cu-SAR-bisPSMA) as they progress through Phase II &amp; Phase III.</li><li>Removal of funding overhang from the stock will be supportive of SP momentum given Clarity still have plenty of data yet to share this year with their SABRE trial, focused on non-PSMA avid prostate cancer diagnosis, the next big catalyst in the coming months. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.12/sh (unrisked $7.71/sh).Clarity have recently completed a $110M institutional equity placement and entitlement offer (with ongoing retail component) that will see them funded through to CY26 including major trial programs for their PSMA directed assets (64Cu/67Cu-SAR-bisPSMA) as they progress through Phase II &amp; Phase III.Removal of funding overhang from the stock will be supportive of SP momentum given Clarity still have plenty of data yet to share this year with their SABRE trial, focused on non-PSMA avid prostate cancer diagnosis, the next big catalyst in the coming months. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - Cash for Copper

Australia

Clarity Pharmaceuticals Limited operates as a radio-pharmaceutical company. The Company focuses on the developing targeted therapies for the treatment of cancer and other serious diseases. Clarity Pharmaceuticals serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Clarity Pharmaceuticals Ltd (CU6 AU)

S&P/ASX Index Rebalance (Dec 2024): CAR, Clarity Pharma Added; Dexus, Spark Deleted

CAR replaces Dexus Property in the ASX50 and Clarity Pharma replaces Spark NZ in the ASX200. This is another big deletion for Dexus and Spark...

Brian Freitas

Clarity Pharmaceuticals (CU6 AU): Well-Funded, Pipeline Progressing Well, Growth Prospects Galore

Clarity Pharmaceuticals doses participants with its lead candidate 64Cu-SAR-bisPSMA and completed final assessment in Phase 2 trial of another...

Tina Banerjee